-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JCLvg3Sgvh3VOvOYBjHtHW+m08HY3GSUriS+VAhX6c2bxQ6wknQJ4Lfu9q1FSRzs QsgYsQTH/W8ewcsvjkT0pA== 0000950134-05-008246.txt : 20050427 0000950134-05-008246.hdr.sgml : 20050427 20050427170704 ACCESSION NUMBER: 0000950134-05-008246 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050421 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20050427 DATE AS OF CHANGE: 20050427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STEMCELLS INC CENTRAL INDEX KEY: 0000883975 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943078125 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19871 FILM NUMBER: 05777203 BUSINESS ADDRESS: STREET 1: 3155 PORTER DRIVE STREET 2: . CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 6504753100 MAIL ADDRESS: STREET 1: 3155 PORTER DRIVE STREET 2: . CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: CYTOTHERAPEUTICS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 f08415e8vk.htm FORM 8-K e8vk
 

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 21, 2005

StemCells, Inc.

(Exact name of registrant as specified in its charter)
         
Delaware
(State or other
jurisdiction
of incorporation) 		  0-19871
(Commission
File Number) 		  94-3078125
(IRS Employer
Identification No.)
     
3155 Porter Drive, Palo Alto, California
(Address of principal executive offices) 		  94304
(Zip Code)

Registrant’s telephone number, including area code: (650) 475-3100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

 

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

     On April 21, 2005, StemCells, Inc. (the “Company”) entered into a Second Amendment to Lease by and between The Board of Trustees of Leland Stanford Junior University and the Company (the “Lease Amendment”) regarding the lease of the Company’s primary office and research facility located at 3155 Porter Drive, Palo Alto, California. The Lease Amendment, effective as of April 1, 2005, extends the term of the lease through March 31, 2010, includes an immediately effective reduction in the rent per square foot, provides for an expansion of the leased premises by approximately 28,000 additional square feet effective July 1, 2006, and provides the Company a renewal option to extend the term of the lease through March 31, 2013.

 

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  STEMCELLS, INC.
 		  
  By:   /s/ Martin McGlynn    
    Martin McGlynn   
    President and Chief Executive Officer   
 

Date: April 27, 2005

 

-----END PRIVACY-ENHANCED MESSAGE-----